经济观察网 派格生物医药-B（02565.HK）股价于2月13日下跌5.54%，收报63.05港元。此次下跌主要受 市场整体走弱、纳入指数利好兑现、技术面承压、资金面分歧及高估值压力等多重因素影响。 从技术指标看，2月13日收盘价63.05港元低于5日均线（65.27港元）和20日均线（65.515港元），且 MACD柱状图虽转正但仍处于零轴下方，短期均线呈空头排列。当日振幅达9.51%，股价一度下探至 61.05港元，触及布林带下轨（58.974港元）附近，反映抛压较强。尽管当日资金整体净流入335.67万港 元，但主要为散户资金推动（净流入335.67万港元），主力资金净流入为0，显示机构观望情绪较浓。 换手率仅0.08%，成交额约1523万港元，流动性相对偏低，放大了个股波动。 公司最新估值 截至2月13日，公司市盈率（TTM）为-101.56倍，市净率达42.84倍，估值水平较高。根据2025年中期业 绩，公司研发开支为2629.4万元，持续投入压力较大。市场可能担忧其盈利前景与当前估值匹配度。 股票近期走势 2月13日，港股主要指数普遍下跌，恒生指数下跌1.72%，生物技术板块整体下跌0.95%。市 ...

以上内容基于公开资料整理，不构成投资建议。 经济观察网 新桥生物（NBP.OQ）在近7天（2026年02月07日至02月13日）股价呈现波动下行趋势，区 间累计下跌11.35%，振幅达13.78%。具体来看，2月9日股价单日大跌6.22%，成交量34.24万股；随后2 月10日至12日连续下跌，跌幅分别为1.44%、0.88%和4.42%，其中2月10日成交量放大至51.28万股；2月 13日小幅反弹1.23%，但成交量萎缩至1.11万股。同期，所属生物技术板块上涨1.80%，公司表现显著弱 于板块。 ...

Core Viewpoint - The recent stock price fluctuations of Tianyan Pharmaceutical (ADAG.OQ) are influenced by technical corrections, clinical data expectations, partnership developments, and overall market sentiment [1] Stock Price Trends - Prior to the drop on February 12, the stock had increased by 17.32% over the previous seven trading days, with a single-day increase of 11.61% on February 10. The significant short-term gains likely prompted profit-taking by some investors, resulting in a 6.45% decline on February 12. However, the stock rebounded by 10.88% on February 13, indicating notable market sentiment volatility [2] Product Development Progress - The development of the company's core product, muzastotug (ADG126), is under market scrutiny. According to a business update released on January 26, 2026, Tianyan Pharmaceutical plans to announce clinical data updates for the drug in combination with pembrolizumab for colorectal cancer in the first quarter of 2026. Additionally, the partnership with Sanofi, involving a strategic investment of up to $25 million, and the FDA's grant of fast track designation may influence investor expectations regarding long-term value [3] Financial Status - As of December 31, 2025, the company reported unaudited cash and cash equivalents of $74.5 million, which is expected to support operations until the end of 2027. This financial stability alleviates market concerns regarding short-term funding pressures [4] Market Environment - On February 12, the Nasdaq index fell by 1.91%, while the biotechnology sector saw a slight increase of 0.78%. However, overall market risk aversion may amplify individual stock volatility. Following a market stabilization on February 13, the biotechnology sector rebounded by 1.86%, contributing to the recovery of Tianyan Pharmaceutical's stock price [5]

第四季度营收为6.78亿美元，高于市场预期的6.251亿美元，尽管同比下滑30%，但美国市场新冠疫苗销 售表现稳健，缓解了投资者对收入持续萎缩的担忧。公司同时重申2026年营收增长目标为10%，传递出 业务企稳信号。 财务状况 2025年全年运营支出预期下调至50亿-52亿美元，较此前指引缩减2亿美元；年末现金储备预计达81亿美 元，高于此前65亿-70亿美元的预测，增强了财务韧性。第四季度每股亏损2.11美元，较去年同期的2.91 美元收窄，反映亏损面收缩。 经济观察网莫德纳(MRNA.O)于2026年2月13日发布2025年第四季度及全年财报后，股价单日大幅上涨 7.58%，收盘报43.15美元，创下年内新高。当日成交额达5.14亿美元，量比1.61，换手率3.05%，显著高 于近期平均水平。 股价异动原因 当日纳斯达克指数上涨0.42%，生物技术板块涨幅1.85%，行业情绪向好。 资金面与技术面 低估值(市盈率TTM为负)与高波动性吸引短期资金流入，单日振幅达8.90%，成交量为近月均值的1.6 倍。 未来发展 流感疫苗审批受挫(FDA以临床试验设计问题拒审mRNA-1010)可能延迟2028年盈亏平衡 ...

以上内容基于公开资料整理，不构成投资建议。 机构评级方面，截至2026年2月11日，经济观察网报道指出，5家机构对康乃德生物维持强力买入建议， 预测目标价均值为7.95美元/股，最高目标价10.07美元/股，机构关注点集中于其T细胞调节平台创新疗 法的长期潜力。 经济观察网近一周(2026年2月9日至13日)，康乃德生物(CNTB.OQ)股价波动显著，流动性较低放大价格 变化。根据内部数据库行情数据，截至2月13日收盘价2.66美元，较2月9日收盘价2.72美元区间下跌 2.21%，但区间振幅达17.28%。单日表现分化：2月9日大涨11.93%至2.72美元，2月10日回调2.57%至 2.65美元，2月11日微涨1.13%至2.68美元，2月12日下跌7.84%至2.47美元，2月13日反弹7.69%至2.66美 元。同期美股生物技术板块整体微涨，但个股换手率持续低位(如2月13日换手率0.02%)，显示流动性有 限易加剧波动。 机构观点 ...

Core Viewpoint - The stock price of ShuoDi Bio has been on a continuous decline despite recent positive developments, indicating a disconnect between market performance and company fundamentals [1][2][4]. Stock Performance - As of February 13, 2026, ShuoDi Bio's stock closed at $71.25, down 1.10% for the day, with a cumulative decline of 4.90% over the past five days and a price fluctuation of 14.82%, reaching a low of $70.05 [1]. - The trading volume showed significant variation, with a peak of $64.05 million on February 12 (turnover rate of 1.24%) and a drop to $21.96 million on February 13 (volume ratio of 1.08) [1]. - The biotechnology sector rose by 1.84%, but ShuoDi Bio's performance lagged behind the broader market, which saw the Nasdaq index decline by 1.54% [1]. Recent Events - On December 30, 2025, ShuoDi Bio entered a non-exclusive patent licensing agreement with Roche and Genentech, receiving a $100 million upfront payment and the right to earn low single-digit royalties on future sales of Genentech's oral GLP-1 drug CT-996 [2]. - This partnership does not restrict the company's core pipeline development and provides non-dilutive funding support, yet the stock price has not reflected this positive news [2]. Financial Analysis - For the third quarter of 2025, ShuoDi Bio reported zero revenue and a net loss of $65.8 million, with a return on equity (ROE) of -25.31%, indicating ongoing pressure on short-term profitability due to R&D investments [3]. - The company has a debt-to-asset ratio of 7.47% and a current ratio of 14.15%, suggesting a solid financial structure despite significant profitability gaps [3]. Institutional Perspectives - Multiple brokerages remain optimistic about ShuoDi Bio's long-term value, primarily due to the cash flow potential from the patent collaboration and the scarcity of the oral GLP-1 pipeline [4]. - However, short-term stock performance is constrained by sector rotation, technical corrections, and market concerns regarding increased competition in the GLP-1 space, leading to significant funding divergence [4].

股价与资金表现 经济观察网根据公开信息，康乃德生物(CNTB.OQ)股价在2026年2月12日出现下跌。行情数据显示，该 股当日收盘价为2.47美元，单日下跌7.84%。从市场表现看，当日美股生物技术板块整体微涨0.24%，但 纳斯达克指数下跌2.03%，显示科技成长股承压可能对个股情绪产生影响。 以上内容基于公开资料整理，不构成投资建议。 需要注意的是，该股票近期波动较大。在2月5日至2月11日的一周内，其股价振幅达到23.61%，并在2 月9日出现单日大涨11.93%后连续两日回调。2月12日的下跌可能包含部分技术性回调因素。同时，个 股换手率较低(0.20%)，流动性有限也可能放大了价格波动。 ...

Group 1: St Barbara and Lingbao Gold Joint Venture - St Barbara Ltd (ASX: SBM) has confirmed a joint venture with Lingbao Gold Group Co., Ltd. for a cash investment of AUD 370 million to acquire a 50%+1 share in St Barbara Mining Pty Ltd, aimed at the Simberi gold mine expansion project [2][3] - The transaction is expected to close by the end of March 2026, coinciding with the final investment decision (FID) for the Simberi project [2][4] - Following the deal, Lingbao Gold will hold an 80% interest in the Simberi project, while Kumul Mineral Holdings will acquire a 20% interest for AUD 100 million, creating a non-corporate joint venture with an 80:20 ownership structure [3][4] Group 2: Project Details and Financial Implications - The Simberi expansion project has existing reserves of approximately 2.5 million ounces (Moz) and resources of about 5.8 Moz, with a competitive cost structure and long-term growth potential [4] - The project is expected to commence production as early as this fiscal year, with annual output projected to gradually increase to 200,000 ounces over five years [4] - The implied overall value of the Simberi project is estimated at around AUD 800 million, surpassing St Barbara's market capitalization of approximately AUD 600 million at the time [3][4] Group 3: Company Background and Market Context - Lingbao Gold is one of China's major gold producers, listed in Hong Kong since 2006, with a comprehensive business model covering exploration, mining, and trading [5] - Kumul Mineral Holdings, as a state-owned enterprise in Papua New Guinea (PNG), provides governmental support for the transaction, reflecting the PNG government's endorsement of the Simberi project [5] - St Barbara's market capitalization also includes other development projects in Canada, cash, gold inventory, and other investment assets, with the Simberi mining lease extended until 2038 [5]

来自伦敦大学学院（UCL）计算机科学系的研究团队提出了一种用于白细胞形态分析的联邦学习框架，使各机构能够在不交换训练数据的情况下进行协同 训练。利用来自多个临床站点的血液涂片，该联邦模型在保证完全数据隐私的同时，学习到稳健且域不变的特征表示。与集中式训练相比，联邦训练在跨 站点性能和对未知机构的泛化能力上表现出色。 血液形态学检查是临床诊断血液疾病的重要环节，通过观察外周血涂片（PBS）或骨髓穿刺（BMA）中的细胞形态，医生可以判断白血病、贫血、感染 及遗传性血液疾病的类型。然而，这一过程不仅劳动强度大，而且高度依赖经验丰富的专业人员。尤其在低收入和中等收入国家（LMICs），技能专家稀 缺，使得快速、可靠且可扩展的血液学诊断成为急需解决的问题。 近年来，人工智能和深度学习的发展为血液形态分析提供了新的解决方案。AI 模型能够自动识别不同类型的白细胞，并辅助医生进行快速诊断。研究表 明，深度学习在自动化血液学诊断中具备显著潜力，但现实应用中仍面临重要挑战——模型训练对数据的依赖性极强，而临床数据通常分布在不同医院， 且存在染色方法差异、成像设备差异以及少数罕见细胞类型的问题。这种数据异质性会导致模型在新机构或 ...

经济观察网中慧生物-B(02627.HK)在近7天(2026年2月9日至13日)股价表现强势，呈现连续上涨态势。 截至2月13日收盘，股价报51.50港元，单日涨幅0.39%，近5日累计涨幅达10.33%，区间振幅为12.47%。 资金动向 资金面上，主力资金持续净流入，2月13日单日主力净流入350.60万港元，近5日主力净流入合计约 917.36万港元，显示机构资金关注度较高。 板块变化情况 板块对比方面，同期港股生物技术板块下跌0.95%，恒生指数下跌1.72%，公司股价逆势走强，凸显相 对韧性。 以上内容基于公开资料整理，不构成投资建议。 ...